WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2026)
Top general drug manufacturer stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best general drug manufacturer stocks to buy now. Learn More.

Industry: Drug Manufacturers - Gene...
OverviewZen RatingPriceValueGrowthFinancialsMomentumSentiment
ForecastDividendsDue Diligence
A
General Drug Manufacturers is Zen Rated A and is the 5th ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
Zen Rating
Sentiment
Market Cap
Shares
Institutional %
Insider %
Net Insider (L12M)
Net Insider (L3M)
LLY
ELI LILLY & CO
$893.19B941,741,40684.21%10.57%Net SellingNet Selling
BMY
BRISTOL MYERS SQUIBB CO
$114.68B2,042,071,24780.27%0.37%Net SellingNet Selling
ABBV
ABBVIE INC
$356.10B1,766,792,82175.00%0.16%Net SellingNet Selling
PFE
PFIZER INC
$146.36B5,699,444,16965.46%0.27%Net SellingNet Buying
GRFS
GRIFOLS SA
$5.57B687,554,90820.87%0.00%
SNY
SANOFI
$105.63B1,219,427,09618.35%0.00%
AZN
ASTRAZENECA PLC
$283.23B1,549,000,00031.71%0.00%Net BuyingNet Buying
BIIB
BIOGEN INC
$28.56B147,637,11794.64%2.15%Net SellingNet Selling
GSK
GSK PLC
$101.40B4,023,000,0009.96%0.00%
MRK
MERCK & CO INC
$275.09B2,469,824,41579.78%0.22%Net BuyingNet Buying
GILD
GILEAD SCIENCES INC
$163.06B1,241,569,87487.88%1.12%Net SellingNet Selling
AMRN
AMARIN CORP PLC
$315.59M419,382,1771.08%15.96%Net SellingNet Selling
AMGN
AMGEN INC
$179.02B539,708,27480.88%1.01%Net SellingNet Selling
JNJ
JOHNSON & JOHNSON
$532.77B2,407,216,97173.93%0.20%Net SellingNet Selling
NVS
NOVARTIS AG
$278.64B1,908,091,9657.03%0.00%
SCLX
SCILEX HOLDING CO
$66.40M8,491,2670.37%99.63%Net Selling
OGN
ORGANON & CO
$3.51B262,600,86275.37%0.52%Net SellingNet Selling
MIRA
MIRA PHARMACEUTICALS INC
$41.48M42,022,0875.27%18.36%Net Buying
NSRX
NASUS PHARMA LTD
$28.40M9,015,3830.03%58.94%Net BuyingNet Buying
MDCX
MEDICUS PHARMA LTD
$13.19M39,362,10910.01%25.14%Net Buying
1

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in May 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:

1. Eli Lilly & Co (NYSE:LLY)


Eli Lilly & Co (NYSE:LLY) is the #1 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Eli Lilly & Co (NYSE:LLY) is: Value: B, Growth: C, Momentum: C, Sentiment: A, Safety: C, Financials: B, and AI: B.

Eli Lilly & Co (NYSE:LLY) has a Due Diligence Score of 62, which is 25 points higher than the general drug manufacturer industry average of 37.

LLY passed 25 out of 38 due diligence checks and has strong fundamentals. Eli Lilly & Co has seen its stock return 26.22% over the past year, underperforming other general drug manufacturer stocks by -2 percentage points.

Eli Lilly & Co has an average 1 year price target of $1,248.84, an upside of 31.67% from Eli Lilly & Co's current stock price of $948.45.

Eli Lilly & Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 19 analysts covering Eli Lilly & Co, 68.42% have issued a Strong Buy rating, 26.32% have issued a Buy, 0% have issued a hold, while 5.26% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Bristol Myers Squibb Co (NYSE:BMY)


Bristol Myers Squibb Co (NYSE:BMY) is the #2 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Bristol Myers Squibb Co (NYSE:BMY) is: Value: A, Growth: C, Momentum: B, Sentiment: C, Safety: B, Financials: B, and AI: C.

Bristol Myers Squibb Co (NYSE:BMY) has a Due Diligence Score of 51, which is 14 points higher than the general drug manufacturer industry average of 37.

BMY passed 18 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock return 19.8% over the past year, underperforming other general drug manufacturer stocks by -8 percentage points.

Bristol Myers Squibb Co has an average 1 year price target of $61.69, an upside of 9.84% from Bristol Myers Squibb Co's current stock price of $56.16.

Bristol Myers Squibb Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 16 analysts covering Bristol Myers Squibb Co, 37.5% have issued a Strong Buy rating, 6.25% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 6.25% have issued a Strong Sell.

3. Abbvie (NYSE:ABBV)


Abbvie (NYSE:ABBV) is the #3 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Abbvie (NYSE:ABBV) is: Value: C, Growth: B, Momentum: C, Sentiment: C, Safety: A, Financials: B, and AI: B.

Abbvie (NYSE:ABBV) has a Due Diligence Score of 31, which is -6 points lower than the general drug manufacturer industry average of 37. Although this number is below the industry average, our proven quant model rates ABBV as a "A".

ABBV passed 11 out of 38 due diligence checks and has average fundamentals. Abbvie has seen its stock return 8.61% over the past year, underperforming other general drug manufacturer stocks by -19 percentage points.

Abbvie has an average 1 year price target of $256.83, an upside of 27.43% from Abbvie's current stock price of $201.55.

Abbvie stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Abbvie, 66.67% have issued a Strong Buy rating, 16.67% have issued a Buy, 16.67% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 14 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Pfizer (NYSE:PFE)


Pfizer (NYSE:PFE) has an annual dividend yield of 5.02%, which is 2 percentage points higher than the general drug manufacturer industry average of 2.78%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of 131.3% indicates that its high dividend yield might not be sustainable for the long-term.

2. Sanofi (NASDAQ:SNY)


Sanofi (NASDAQ:SNY) has an annual dividend yield of 4.08%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.78%. Sanofi's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 58.1% indicates that its high dividend yield is sustainable for the long-term.

3. Gsk (NYSE:GSK)


Gsk (NYSE:GSK) has an annual dividend yield of 3.49%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.78%. Gsk's dividend payout is not stable, having dropped more than 10% eight times in the last 10 years. Gsk's dividend has not shown consistent growth over the last 10 years.

Gsk's dividend payout ratio of 45% indicates that its dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks down?

General drug manufacturer stocks were down -1.02% in the last day, and down -1.07% over the last week. Pfizer was the among the top losers in the drug manufacturers - general industry, dropping -3.02% yesterday.

Shares of pharmaceutical companies are trading lower. Recent reports suggest that Health and Human Services Secretary Kennedy is exploring the ban of some widely used antidepressants.

What are the most undervalued general drug manufacturer stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued general drug manufacturer stocks right now are:

1. Biogen (NASDAQ:BIIB)


Biogen (NASDAQ:BIIB) is the most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 86, which is 50 points higher than the general drug manufacturer industry average of 36. It passed 6 out of 7 valuation due diligence checks.

Biogen's stock has gained 63.4% in the past year. It has overperformed other stocks in the general drug manufacturer industry by 35 percentage points.

2. Bristol Myers Squibb Co (NYSE:BMY)


Bristol Myers Squibb Co (NYSE:BMY) is the second most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Bristol Myers Squibb Co has a valuation score of 57, which is 21 points higher than the general drug manufacturer industry average of 36. It passed 4 out of 7 valuation due diligence checks.

Bristol Myers Squibb Co's stock has gained 19.8% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -8 percentage points.

3. Gsk (NYSE:GSK)


Gsk (NYSE:GSK) is the third most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Gsk has a valuation score of 43, which is 7 points higher than the general drug manufacturer industry average of 36. It passed 3 out of 7 valuation due diligence checks.

Gsk's stock has gained 36.72% in the past year. It has overperformed other stocks in the general drug manufacturer industry by 9 percentage points.

Are general drug manufacturer stocks a good buy now?

50% of general drug manufacturer stocks rated by analysts are a buy right now. On average, analysts expect general drug manufacturer stocks to rise by 22.54% over the next year.

18.75% of general drug manufacturer stocks have a Zen Rating of A (Strong Buy), 43.75% of general drug manufacturer stocks are rated B (Buy), 31.25% are rated C (Hold), 0% are rated D (Sell), and 6.25% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 33.42x.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.